Health Care · Biological Products, (No Diagnostic Substances) · Nasdaq · CIK 1613780 · FYE Dec 31 · Prices AT CLOSE 2026-07-29 (USD) — end-of-day, never a live or intraday quote
Last $13.73Day +1.70%Mkt cap $4.1B1Y +40.1%Off 52W high −47.6%Vol (1Y) 76.2%
Daily closing price, split-adjusted to the current basis; 3y shown of 2,818 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest0.5% of sh out |
| Days to cover7.8d |
| 13F net flow (QoQ)+0.91% |
| Top-10 13F concentration81.2% |
| Next report (est.)2026-10-14 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Sales (TTM)$4.9M |
| Earnings (TTM)-$175.9M |
| ROE−149.8% |
| Net margin−2607.3% |
| Sales growth 3Y5.2% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD−28.4% |
| 1Y+40.1% |
| 3Y+363.9% |
| 5Y+26.7% |
| 10Y−80.2% |
| Since incept. (ann.)−9.7% |
Price return through 2026-07-29 · series begins 2014-10-22. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)76.2% |
| Ann. volatility (3Y)322.4% |
| Sharpe (1Y)0.82 |
| Sharpe (3Y)0.63 |
| Max drawdown (1Y)−45.0% |
| Max drawdown (3Y)−86.6% |
| Beta (3Y vs SPY)2.79 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| MPM BIOIMPACT LLC | 5.2M | $109M | 1.76% | +423.0% |
| Vivo Capital, LLC | 2.7M | $56M | 0.90% | +8.4% |
| Artisan Partners Limited Partnership | 2.2M | $46M | 0.75% | −32.9% |
| Siren, L.L.C. | 1.9M | $39M | 0.63% | +0.0% |
| BAKER BROS. ADVISORS LP | 1.5M | $31M | 0.49% | +0.0% |
| ADAR1 Capital Management, LLC | 1.0M | $21M | 0.34% | new |
| PERCEPTIVE ADVISORS LLC | 964,391 | $20M | 0.33% | new |
| Patient Square Capital LP | 693,534 | $14M | 0.23% | +93.2% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-06-30 | 2026-07-16 | −$0.12 | — | $700,000 | −53.3% |
| 2026-03-31 | 2026-04-30 | −$0.11 | — | $900,000 | +12.5% |
| 2025-12-31 | 2026-03-26 | — | — | $562,000 | +10.0% |
| 2025-09-30 | 2025-10-28 | −$0.24 | — | $2.8M | +158.8% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-10-14 is ESTIMATED from filing cadence (median gap 90d) — not company-confirmed.
